Drug Profile
Research programme: anti-angiogenic ocular gene therapies - Advanced Vision Therapies
Alternative Names: AVT-1; AVT-2Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Advanced Vision Therapies
- Class Gene therapies
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Age-related macular degeneration; Diabetic retinopathy; Retinitis pigmentosa
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Ophthalmic)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA (Ophthalmic)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Retinitis-pigmentosa in USA (Ophthalmic)